Bookmarks
Coagulopathies & arterial/venous thrombosis in COVID patients: an OMOP dataset
Population Size
50,899
People
Years
2020 - 2020
Associated BioSamples
None/not available
Geographic coverage
United Kingdom
England
Lead time
1-2 months
Summary
Documentation
In December 2019, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was described and by March 2020, the World Health Organization had declared the disease (Coronavirus disease 2019, COVID-19) a pandemic. Whilst respiratory symptoms are the fundamental feature of the disease, evidence indicates that the disease is associated with coagulation dysfunction which predisposes patients to an increased risk of both venous and arterial thromboembolism (TE) and potentially increased mortality risk as a consequence. Biomarkers associated with TE (D-dimers) are often raised in people with COVID but without clear evidence of TE. It is important to understand who is at most risk of TE, to manage disease effectively. This dataset (in OMOP) describes patients with and without COVID who were admitted to UHB including all those with and without TE.
PIONEER geography The West Midlands (WM) has a population of 5.9 million & includes a diverse ethnic & socio-economic mix. Birmingham was hard hit by all COVID waves and University Hospitals Birmingham NHS Foundation Trust (UHB) had >8000 COVID admissions by the end of December 2020.
EHR. UHB is one of the largest NHS Trusts in England, providing direct acute services & specialist care across four hospital sites, with 2.2 million patient episodes per year, 2750 beds & an expanded 250 ITU bed capacity during COVID. UHB runs a fully electronic healthcare record (EHR) (PICS; Birmingham Systems), a shared primary & secondary care record (Your Care Connected) & a patient portal “My Health”.
Scope: All patients admitted during the first wave of the COVID-19, both with and without COVID. The dataset includes highly granular patient demographics & co-morbidities taken from ICD-10 & SNOMED-CT codes. Serial, structured data pertaining to acute care process (timings, staff grades, specialty review, wards), presenting complaint, SARS-CoV-2 swab result, diagnosis of TE, clotting parameters, D-Dimers, acuity, all physiology readings (pulse, blood pressure, respiratory rate, oxygen saturations), all blood results, imaging reports, all prescribed & administered treatments (fluids, antibiotics, inotropes, vasopressors, organ support), all outcomes.
Available supplementary data: Matched controls; ambulance, synthetic data.
Available supplementary support: Analytics, Model build, validation & refinement; A.I.; Data partner support for ETL (extract, transform & load) process, Clinical expertise, Patient & end-user access, Purchaser access, Regulatory requirements, Data-driven trials, “fast screen” services.
Dataset type
Dataset sub-type
Dataset population size
Keywords
Observations
Observed Node | Disambiguating Description | Measured Value | Measured Property | Observation Date |
---|---|---|---|---|
Persons | 50,899 patients including Coagulopathy and Non-Coagulopathy control group. | 50899 | Count | 09 Dec 2020 |
Provenance
Purpose of dataset collection
Source of data extraction
Collection source setting
Patient pathway description
Image contrast
Biological sample availability
Structural Metadata
Details
Publishing frequency
Version
Modified
08/10/2024
Distribution release date
11/08/2020
Citation Requirements
Coverage
Start date
01/01/2020
End date
08/09/2020
Time lag
Geographic coverage
Minimum age range
Maximum age range
Follow-up
Accessibility
Language
Alignment with standardised data models
Controlled vocabulary
Format
Data Access Request
Dataset pipeline status
Time to dataset access
Access request cost
Access method category
Access service description
Trusted Research Environments (TRE) are built using Microsoft Azure services and hosted in the UK to provide research teams a safe, secure and agile environment which allows users to quickly analyse, interpret and form an enriched view of primary care information through a range of integrated datasets.
Health data collated from multiple sources is ingested into a secure data lake which will then allow subsets of data to be made available to research teams on approval of a data request. Once approved a customer specific TRE is made available with a standard set of leading analytical tools from Microsoft including Azure Databricks, Azure Machine Learning, Azure SQL and Azure Synapse (for large-scale data warehouses). Specific tools can be provided at an additional cost over the standard platform data access charge and the PIONEER team will work with you to determine your exact needs.
Access to the TRE is managed using the latest virtual desktop technology to provide a safe and secure end-user experience. By utilising leading edge design PIONEER are able to create TREs rapidly to enable us to service any customer requirement.
Data use limitation
Data use requirements
Data Controller